[1] BARTZIOKAS K, PAPAPORFYRIOU A, HILLAS G, et al. Global initiative for chronic obstructive lung disease (GOLD) recommendations: strengths and concerns for future needs[J]. Postgrad Med, 2023, 135(4):327-333. [2] CHEN J, YIN Y, ZHANG Y, et al. Chronic obstructive pulmonary disease prevalence and associated risk factors in adults aged 40 years and older in southeast china: a cross-sectional study during 2019-2020[J]. Int J Chron Obstruct Pulmon Dis, 2022, 17:2317-2328. [3] PHILLIPS T M, MOLONEY C, SNEATH E, et al. Associated factors, assessment, management, and outcomes of patients who present to the emergency department for acute exacerbation of chronic obstructive pulmonary disease: a scoping review[J]. Respir Med, 2022, 193:106747. [4] KAUR D, MEHTA R L, JARRETT H, et al. Phase III, two arm, multi-centre, open label, parallel-group randomised designed clinical investigation of the use of a personalised early warning decision support system to predict and prevent acute exacerbations of chronic obstructive pulmonary disease: ‘Predict & Prevent AECOPD’ - study protocol[J]. BMJ Open, 2023, 13(3):e061050. [5] RYAN E M, SADIKU P, COELHO P, et al. NRF2 activation reprograms defects in oxidative metabolism to restore macrophage function in chronic obstructive pulmonary disease[J]. Am J Respir Crit Care Med, 2023, 207(8):998-1011. [6] 李慧娇, 王一萍, 何薇, 等. 慢性阻塞性肺疾病患者血清可溶性基质裂解素2、白细胞介素-33水平及其与疾病严重程度的关系研究[J]. 中国卫生检验杂志, 2021, 31(17):2102-2104, 2108. [7] 中华医学会, 中华医学会杂志社, 中华医学会全科医学分会, 等. 慢性阻塞性肺疾病基层诊疗指南(2018年)[J]. 中华全科医师杂志, 2018, 17(11):856-870. [8] WANG Z, LOCANTORE N, HALDAR K, et al. Inflammatory endotype-associated airway microbiome in chronic obstructive pulmonary disease clinical stability and exacerbations: a multicohort longitudinal analysis[J]. Am J Respir Crit Care Med, 2021, 203(12):1488-1502. [9] 伍桂雄, 董树烽, 农美蓉, 等. 慢性阻塞性肺疾病急性加重期患者血清CCL18、IL-17水平的变化及临床意义[J]. 中国医师杂志, 2021, 23(7):1073-1077. [10] 严英, 刘博伟, 马春明, 等. 慢性阻塞性肺疾病急性加重期患者死亡风险预测模型构建及效能验证[J]. 山东医药, 2021, 61(3):51-55. [11] HSIEH M H, CHEN P C, HSU H Y, et al. Surfactant protein D inhibits lipid-laden foamy macrophages and lung inflammation in chronic obstructive pulmonary disease[J]. Cell Mol Immunol, 2023, 20(1):38-50. [12] YOUSUF A J, MOHAMMED S, CARR L, et al. Astegolimab, an anti-ST2, in chronic obstructive pulmonary disease (COPD-ST2OP): a phase 2a, placebo-controlled trial[J]. Lancet Respir Med, 2022, 10(5):469-477. [13] 陈志勇, 罗世林, 张健, 等. 慢阻肺患者血清IL-17,IL-27和IL-33水平表达及与不同临床分期FeNO和肺功能的相关性研究[J]. 现代检验医学杂志, 2021, 36(4):152-155, 166. [14] SINGH H, KHURANA A, KUMAR A, et al. Serum levels of interleukin-33, soluble ST2 and IgE in patients with asthma: a case-control study[J]. J Asthma, 2024, 61(1):48-57. [15] 张曙晴, 张骆军, 周小林,等. 慢性阻塞性肺疾病患者血清IL-33、sST2、CRP水平与病情严重程度的相关性研究[J]. 中国实验诊断学, 2021, 25(11):1610-1613. [16] URBAN M H, STOJKOVIC S, DEMYANETS S, et al. Soluble ST2 and all-cause mortality in patients with chronic obstructive pulmonary disease—a 10-year cohort study[J]. J Clin Med, 2021, 11(1):56. [17] 张绍塘, 陈伦, 叶健. 多索茶碱联合盐酸氨溴索对老年稳定期慢阻肺患者血清IL-33/sST2轴表达的影响[J]. 中国临床药理学杂志, 2022, 38(4):291-295. |